origin
isol
swine
propos
influenza
viru
sinc
shown
common
cattl
inocul
idv
calv
result
mild
respiratori
diseas
histolog
character
tracheiti
sever
studi
associ
presenc
idv
acut
bovin
respiratori
diseas
brd
sought
investig
efficaci
inactiv
idv
vaccin
vaccin
calv
seroconvert
hemagglutin
inhibit
titer
follow
two
dose
nonvaccin
calv
challeng
homolog
viru
exhibit
sign
mild
respiratori
diseas
day
four
ten
post
challeng
significantli
differ
neg
control
day
five
nine
post
challeng
peak
viral
shed
approxim
tcid
ml
measur
nasal
tracheal
swab
bronchoalveolar
lavag
fluid
four
six
day
post
challeng
viral
titer
significantli
p
decreas
tcid
ml
tcid
ml
tcid
ml
respect
aforement
sampl
collect
vaccin
anim
compar
nonvaccin
control
peak
shed
viral
antigen
detect
respiratori
epithelium
nasal
turbin
trachea
immunohistochemistri
unvaccin
calv
significantli
fewer
vaccin
inflamm
character
neutrophil
observ
nasal
turbin
trachea
appreci
lung
togeth
result
support
etiolog
role
idv
brd
demonstr
partial
protect
afford
inactiv
vaccin
first
isol
pig
acut
respiratori
diseas
propos
influenza
viru
subsequ
identifi
bovin
numer
countri
includ
unit
state
mexico
itali
franc
china
well
sow
itali
haus
et
al
haus
et
al
ferguson
et
al
collin
et
al
mitra
et
al
ducatez
et
al
chiapponi
et
al
jiang
et
al
serolog
survey
swine
human
sera
found
low
antibodi
preval
respect
sever
studi
found
idv
antibodi
nearli
ubiquit
bovin
haus
et
al
haus
et
al
ferguson
et
al
result
addit
common
detect
isol
idv
bovin
acut
respiratori
diseas
led
propos
cattl
reservoir
idv
haus
et
al
besid
swine
human
bovin
idv
antibodi
also
detect
goat
sheep
absent
poultri
quast
et
al
viral
metagenom
sequenc
calv
acut
respiratori
diseas
asymptomat
control
larg
ranch
use
identifi
virus
associ
bovin
respiratori
diseas
brd
ng
et
al
bovin
adenoviru
bovin
rhiniti
viru
idv
virus
significantli
associ
brd
p
similarli
viral
metagenom
sequenc
feedlot
cattl
acut
brd
healthi
pen
mate
ten
site
mexico
us
identifi
twenti
one
differ
virus
howev
idv
viru
moder
associ
brd
odd
ratio
p
mitra
et
al
amount
idv
rna
sampl
anim
brd
also
significantli
greater
idvposit
asymptomat
anim
p
separ
studi
found
much
higher
incid
idv
respiratori
swab
taken
calv
acut
brd
compar
healthi
calv
mississippi
cattl
orderbuy
facil
ferguson
et
al
recent
pathogenesi
idv
investig
limit
number
calv
ferguson
et
al
calv
inocul
idv
display
mild
respiratori
diseas
similar
control
viru
replic
detect
respiratori
tract
associ
signific
increas
neutrophil
trachea
idv
transmit
contact
anim
inocul
expos
anim
seroconvert
conclus
establish
mount
evid
suggest
idv
part
bovin
respiratori
diseas
complex
brdc
econom
signific
diseas
affect
us
cattl
industri
object
studi
investig
idv
pathogenesi
determin
inactiv
vaccin
afford
protect
diseas
caus
idv
anim
procedur
perform
midwest
veterinari
servic
mv
use
biosafeti
level
practic
protocol
approv
institut
anim
care
use
committe
iacuc
mv
sixti
five
approxim
sixmonth
old
calv
receiv
colostrum
purchas
singl
farm
transport
mv
anim
hemagglutin
inhibit
hi
titer
neg
bovin
virus
detect
kansa
state
veterinari
diagnost
laboratori
ksvdl
brd
pcr
panel
idv
bovin
viral
diarrhea
viru
bovin
herpesviru
bovin
respiratori
syncyti
viru
bovin
coronaviru
prior
transport
studi
initi
human
rector
tumor
swine
testicl
st
cell
maintain
minim
essenti
media
mem
supplement
fetal
bovin
serum
lglutamin
c
co
strain
isol
cell
nasal
swab
submit
ksvdl
brd
diagnost
test
viru
passag
cell
titrat
st
cell
determin
tissu
cultur
infect
dose
per
ml
tcid
propag
idv
util
mem
supplement
mgml
trypsin
st
trypsin
omit
sampl
nasal
swab
tracheal
swab
bronchoavleolar
lavag
fluid
analyz
quantit
revers
transcript
pcr
qrtpcr
idv
previous
describ
haus
et
al
rna
extract
cultur
titer
tcid
ml
serial
dilut
analyz
qrtpcr
gener
standard
curv
correl
cycl
threshold
ct
valu
tcid
ml
hemagglutin
hemagglutin
inhibit
assay
perform
use
turkey
red
blood
cell
previous
describ
titer
log
transform
mean
group
titer
calcul
time
point
sever
flask
inocul
multipl
infect
cell
harvest
freezethaw
cycl
viral
titer
determin
hemagglutin
assay
ha
viru
inactiv
bpropiolacton
h
c
antigen
dilut
mem
commerci
adjuv
emulsigen
mvp
biolog
ad
inactiv
viral
fluid
final
volum
ha
concentr
vaccin
ha
unit
per
ml
vaccin
administ
ml
dose
given
subcutan
neck
calv
randomli
assign
one
three
treatment
group
treatment
group
n
calv
receiv
vaccin
day
move
separ
hous
prior
challeng
treatment
group
treatment
group
n
calv
mock
vaccin
day
mem
challeng
day
treatment
group
n
calv
vaccin
day
challeng
day
challeng
viru
dilut
tcid
ml
mem
administ
intranas
ml
instil
nostril
anim
experiment
procedur
conduct
blind
studi
member
bodi
weight
temperatur
determin
rectal
record
day
temperatur
record
begin
day
daili
day
blood
collect
day
nasal
swab
collect
day
calv
observ
advers
event
follow
vaccin
administr
calv
also
observ
daili
begin
day
clinic
sign
diseas
assign
score
normal
mild
moder
sever
separ
depress
respiratori
distress
bodi
condit
mild
clinic
sign
includ
lethargi
slightli
increas
respiratori
rate
abnorm
nasal
ocular
discharg
andor
cough
fat
flank
dehydr
rough
hair
coat
moder
clinic
sign
includ
inact
increas
respiratori
rate
mucopurul
nasal
ocular
discharg
concav
flank
dehydr
andor
rough
hair
coat
sever
clinic
sign
includ
recumb
respiratori
distress
promin
skeletur
sever
dehydr
composit
clinic
score
calcul
summat
depress
bodi
condit
respiratori
distress
score
treatment
group
day
divid
number
calv
treatment
group
three
calv
five
calv
human
euthan
day
necropsi
lung
remov
toto
bronchoalveolar
lavag
fluid
balf
tracheobronchi
lymph
node
specimen
collect
percentag
lung
consolid
estim
lung
lobe
total
lung
consolid
score
calcul
estim
lung
lobe
volum
percentag
whole
apic
lobe
diaphragmat
lobe
cardiac
lobe
accessori
lobe
tracheal
swab
also
collect
necropsi
day
tissu
sampl
includ
lung
trachea
nasal
turbin
collect
euthan
cattl
preserv
neutral
formalin
repres
tissu
collect
middl
trachea
differ
lung
lobe
differ
anim
select
grossli
base
lung
consolid
tissu
sampl
routin
process
histopatholog
section
kansa
state
veterinari
diagnost
laboratori
ksvdl
histopatholog
examin
perform
hematoxylin
eosin
stain
slide
immunohistochem
stain
perform
formalin
fix
paraffin
embed
tissu
section
mm
thick
onto
posit
charg
slide
slide
stain
use
leica
bondmax
autostain
polym
refin
red
detect
kit
polyclon
antisera
rabbit
hyperimmun
dilut
bond
primari
antibodi
diluent
leica
biosystem
trisbuff
salin
heat
mediat
epitop
retriev
perform
use
edta
ph
min
c
tissu
section
incub
primari
antibodi
min
ambient
temperatur
polymer
perform
polymerap
arabbit
leica
biosystem
min
ambient
temperatur
visual
done
fast
red
slide
counterstain
hematoxylin
immunohistochemistri
record
posit
neg
present
number
anim
treatment
group
posit
lung
consolid
hi
titer
idv
titer
nasal
swab
tracheal
swab
balf
analyz
analysi
varianc
anova
use
jmp
softwar
packag
sa
cari
nc
p
consid
signific
signific
differ
identifi
studi
group
mean
pairwis
comparison
perform
tukeykram
test
composit
clinic
sign
depress
bodi
score
respiratori
distress
individu
day
postchalleng
presenc
idv
nasal
turbin
trachea
ihc
analyz
analysi
variant
anova
use
graphpad
prism
graphpad
softar
la
jolla
ca
valu
assign
posit
ihc
sampl
valu
assign
neg
ihc
sampl
kruskalw
test
use
analyz
composit
clinic
score
ihc
score
respons
variabl
shown
signific
effect
treatment
group
subject
pairwis
comparison
use
tukeykram
test
dunn
test
bonferroni
correct
result
studi
commenc
mean
group
idv
hi
titer
log
statist
indistinguish
tabl
increas
less
titer
observ
day
booster
vaccin
administ
day
vaccin
group
significantli
higher
mean
hi
titer
log
nonvaccin
group
log
less
increas
hi
titer
observ
nonvaccin
anim
day
suggest
lack
idv
exposur
prior
challeng
calv
clinic
normal
calv
vaccin
remain
clinic
normal
throughout
studi
composit
clinic
sign
signific
differ
rectal
temperatur
group
day
challeng
phase
experi
group
challeng
idv
mean
clinic
composit
score
begin
day
throughout
remaind
studi
tabl
mean
composit
clinic
score
nonvaccinatedchalleng
group
day
significantli
greater
neg
challeng
control
suggest
idv
caus
mild
respiratori
diseas
subset
nasal
swab
collect
day
three
per
group
addit
analyz
full
ksvdl
brd
pcr
panel
detect
virus
bacteria
associ
brd
bovin
viral
diarrhea
viru
bovin
herpesviru
bovin
respiratori
syncyti
viru
bovin
coronaviru
idv
mycoplasma
bovi
pasteurella
multocida
mannheimia
haemolytica
histophilu
somni
organ
detect
p
multocida
ct
valu
p
multocida
known
commens
inhabit
bovin
respiratori
system
opportunist
pathogen
biberstein
calv
neg
idv
pcr
day
challeng
day
remain
neg
challeng
phase
studi
significantli
higher
idv
titer
nasal
swab
tabl
mean
composit
clinic
score
calv
challeng
idv
day
calv
assign
score
normal
sever
separ
depress
bodi
condit
respiratori
distress
mean
composit
clinic
score
calcul
summat
depress
bodi
condit
respiratori
distress
score
treatment
group
day
divid
number
calv
treatment
group
differ
letter
b
c
indic
signific
differ
p
group
within
column
group
letter
indic
differ
group
day
fig
peak
shed
approxim
tcid
ml
observ
day
homolog
idv
vaccin
significantli
reduc
idv
shed
nasal
swab
tcid
ml
maxim
idv
titer
tracheal
swab
similar
determin
nasal
swab
tcid
ml
detect
day
fig
signific
differ
idv
titer
tracheal
swab
vaccin
nonvaccin
anim
versu
tcid
ml
respect
day
greater
observ
nasal
swab
idv
detect
balf
calv
day
highest
titer
day
fig
interestingli
vaccin
calv
group
posit
day
rel
low
titer
tcid
ml
routin
histolog
nasal
turbin
challeng
calv
small
number
neutrophil
submucosa
neutrophil
exocytosi
mild
multifoc
loss
cilia
fig
three
calv
suppur
rhiniti
character
neutrophil
admix
mucou
overli
respiratori
epithelium
lesion
similar
trachea
consist
small
number
neutrophil
submucosa
neutrophil
exocytosi
occasion
loss
cilia
flatten
epithelium
mild
lymphoplasmacyt
tracheiti
two
calv
layer
mucou
admix
neutrophil
overli
tracheal
mucosa
one
calf
mild
suppur
bronchiti
bronchiol
lung
signific
lesion
observ
tracheobronchi
lymph
node
posit
antigen
deposit
present
cytoplasm
stain
respiratori
epithelium
nasal
turbin
trachea
fig
nasal
turbin
one
five
calv
posit
day
idv
ihc
fig
day
sampl
posit
sampl
group
remain
neg
singl
calf
posit
day
day
sampl
neg
contrast
pcr
idv
detect
nasal
tracheal
swab
balf
nasal
turbin
sampl
neg
ihc
two
five
anim
sampl
posit
ihc
tracheal
sampl
day
fig
lower
posit
tracheal
sampl
day
similar
nasal
turbin
ihc
tracheal
sampl
posit
sampl
day
fig
ihc
also
perform
lung
tissu
howev
two
calv
weakli
posit
respiratori
e
neg
stain
nasal
turbin
respiratori
epithelium
calf
nasal
turbin
calv
group
neg
f
posit
intens
cytoplasm
stain
trachea
respiratori
epithelium
calf
figur
ae
antibodi
polyclon
produc
nonspecif
background
stain
blood
vessel
submucosa
b
nonspecif
stain
cilia
mucou
layer
respiratori
epithelium
figur
taken
magnif
epithelium
airway
tracheobronchi
lymph
node
neg
ihc
idv
bovin
respiratori
diseas
signific
diseas
affect
unit
state
cattl
industri
caus
annual
estim
loss
excess
one
billion
dollar
mcvey
griffin
snowder
et
al
numer
commerci
vaccin
variabl
consist
combin
inactiv
modifi
live
bacteria
virus
wide
use
howev
incid
brd
increas
past
sever
decad
usda
etiolog
brd
involv
interact
host
environ
pathogen
mosier
dogma
posit
anim
stress
often
due
movement
anim
manag
predispos
cattl
primari
viral
insult
follow
secondari
bacteri
pneumonia
due
commens
exogen
pathogen
number
virus
establish
role
brd
pathogenesi
includ
bovin
viral
diarrhea
viru
ridpath
bovin
herpesviru
muylken
et
al
bovin
respiratori
syncyti
viru
gershwin
et
al
bovin
parainfluenza
viru
elli
bovin
rhiniti
viru
mohanti
et
al
bett
et
al
recent
idv
ferguson
et
al
commerci
vaccin
latter
viru
avail
howev
like
part
due
recent
discoveri
develop
understand
role
brd
pathogenesi
show
inactiv
idv
vaccin
provid
partial
protect
diseas
caus
homolog
challeng
signific
reduct
viral
titer
nasal
swab
tracheal
swab
balf
observ
well
number
anim
posit
antigen
nasal
turbin
tracheal
tissu
studi
expand
upon
earlier
idv
pathogenesi
transmiss
studi
perform
small
number
calv
similar
work
idv
replic
limit
upper
respiratori
tract
main
patholog
observ
rhiniti
tracheiti
studi
ferguson
et
al
show
idv
caus
mild
respiratori
diseas
highest
viral
titer
present
nasal
turbin
decreas
tissu
lower
respiratori
tract
also
measur
high
tcid
ml
titer
turbin
trachea
similar
titer
determin
balf
surprisingli
two
calv
weakli
posit
idv
ihc
lung
tissu
suspect
viru
identifi
balf
larg
result
viru
deposit
due
larg
volum
mucou
exud
observ
upper
respiratori
tract
oppos
signific
replic
lung
patholog
seen
lung
one
calf
idv
antigen
deposit
lung
two
calv
demonstr
viru
although
primarili
upper
respiratori
tract
pathogen
abil
replic
lung
extens
lung
import
consid
case
highli
stress
cattl
develop
brd
idv
thought
util
acid
cellular
receptor
haus
et
al
receptor
also
util
bovin
coronaviru
cellular
attach
challeng
studi
shown
bcv
caus
lung
patholog
readili
detect
lung
tissu
ihc
vlasak
et
al
park
et
al
factor
cell
receptor
may
restrict
idv
replic
mainli
upper
respiratori
tract
idv
replic
similarli
restrict
upper
respiratori
tract
swine
ferret
contrast
high
lung
titer
abund
antigen
detect
guinea
pig
lung
haus
et
al
sreenivasan
et
al
swine
inactiv
influenza
viru
vaccin
often
yield
steril
immun
homolog
challeng
vincent
et
al
signific
reduct
viral
titer
nasal
tracheal
swab
balf
observ
addit
signific
reduct
number
anim
posit
idv
ihc
turbin
tracheal
tissu
viral
titer
significantli
greater
nonchalleng
control
observ
calv
use
studi
receiv
colostrum
birth
measur
idv
antibodi
titer
studi
commenc
log
hi
titer
certain
antibodi
matern
deriv
previou
work
found
neonat
beef
cattl
seroposit
idv
ferguson
et
al
prescreen
calv
month
studi
enrol
show
neg
idv
pcr
matern
antibodi
known
interfer
vaccin
develop
activ
immun
presenc
antibodi
time
vaccin
may
lessen
immun
respons
vaccin
sandbult
et
al
human
hi
titer
log
gener
consid
protect
howev
fulli
allevi
diseas
symptom
memoli
et
al
two
dose
inactiv
vaccin
result
hi
titer
log
yield
partial
protect
interestingli
reduct
viral
titer
pronounc
sampl
collect
lower
respiratori
tract
balf
trachea
turbin
inactiv
influenza
vaccin
larg
elicit
protect
humor
immun
result
may
suggest
greater
role
humor
immun
lower
respiratori
tract
result
add
grow
bodi
data
idv
play
etiolog
role
brd
pathogenesi
although
signific
clinic
diseas
caus
idv
mild
may
suffici
allow
infiltr
colon
bacteria
upper
lower
respiratori
tract
ferguson
et
al
futur
studi
need
test
hypothesi
addit
inactiv
idv
vaccin
moder
protect
homolog
challeng
inclus
idv
commerci
brd
vaccin
may
improv
efficaci
prevent
brd
sever
studi
fail
find
evid
widespread
idv
infect
human
haus
et
al
smith
et
al
recent
studi
found
human
occup
expos
cattl
serolog
posit
idv
microneutr
contrast
nonexpos
human
white
et
al
unknown
whether
infect
human
idv
caus
diseas
vaccin
cattl
could
help
limit
zoonosi
